Serum PSA levels have been utilized as a prostate cancer biomarker for over 21 years. But, PSA has intrinsic limitations. The information from PSA level study does not give enough information about the tumor so that clinicians and patients confidently choose between active surveillance strategy and biopsy. Up to 50% of men who have undergone surgical or other therapeutic interventions to treat their PCa likely had indolent, slow-growing tumors that would never have become a threat to their lifespan or health. For those patients the subsequent therapies and prostate tissue biopsies are unnecessary. Hence appropriate incorporation of biomarkers into clinical practice can reduce the unnecessary stress, depression and anxiety of patient, his relatives and caregivers. It also elevates the cost of treatment. Our preliminary data reflects that urinary EV (mRNA+ miRNA) biomarker panel can distinguish biopsy negative and biopsy positive patients with high accuracy (AUC=0.85) and 88.5% specificity. On top the information holds promise to discriminate between indolent and more aggressive, high-risk prostate tumors. The research described in this proposal will use blood sample from 12patients (6patient with Gleason score 6 and6patients with Gleason score ≥7). The different level of cancer samples will give our team the opportunity to study biomarker to distinguish between different stages of cancer. We have 6plasma samples who does not have cancer but went through the same procedure as patients.